Targeting the Brain: Are Nanodrugs Ready for Clinical Translation in CNS Disorders?
Although significant progress has been made in nanotechnology, the clinical translation of central nervous system (CNS) therapeutics has been limited. While engineered nanocarriers have greatly enhanced blood-brain barrier (BBB) transport, there is now growing evidence that enhanced brain delivery is not sufficient for...